Continuing Education Activities
Here at JADPRO CE, you can find a valuable array of certified educational opportunities: it’s the place to get your credits and update your learning in oncology. We provide advanced practitioners like you with a wide range of continuing education, covering the most current topics in several formats so you can choose the way you want to learn. You'll find that our CE offerings are easy to navigate. You can sort by topic and/or format, or simply browse the site and get started!
CAR T-Cell Therapy and the Pharmacology of Managing Cytokine Release Syndrome
Learn from two experts on how to identify patients who meet criteria as candidates for CAR T-cell therapy and apply strategies to mitigate associated serious side effects, including cytokine release syndrome.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Sequencing Therapies in Indolent Lymphomas (FL and CLL)
Discover current best practices for treating follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), including monitoring patients with CLL for 17p deletion at diagnosis and throughout the course of the disease and current and emerging data supporting combination therapies in CLL and novel targeted therapies for newly diagnosed and relapsed/refractory FL.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Therapeutic Advances in Prostate Cancer
Learn from two experts in the field of prostate cancer as they discuss clinical data of emerging and current agents for the treatment of non-metastatic castration-resistant prostate cancer for rapidly rising prostate-specific antigen levels, the role of docetaxel and abiraterone in newly diagnosed metastatic disease, emerging data on the role of genomics in metastatic castration-sensitive and -resistant disease, and strategies to manage toxicities of current and emerging treatments.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Evolving Strategies to Manage Treatment-Related Adverse Events for Patients with Classical Hodgkin Lymphoma
Discover how to prevent and mitigate adverse events of established and emerging cytotoxic regimens, novel agents, and checkpoint inhibitors used to treat classical Hodgkin lymphoma, including best practices and emerging data.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
New Directions in Myeloid Malignancies
Review strategies to monitor minimal residual disease in myeloid malignancies, as well as the safety and efficacy of novel treatment approaches and associated mutations such as IDH2, TP53, FLT3, BCL2, and cell surface antigen CD33.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Sequencing of Treatments for Patients With Ovarian Cancer
Take a deep dive into the history of ovarian cancer treatment, evaluate current options for first-line and maintenance therapy, and review safety and efficacy data for PARP inhibitors alone and in combination with immunotherapy or anti-angiogenic agents.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
New Drug Updates in Hematologic Malignancies
Discover the latest pharmacology and indication approvals for the management of patients with hematologic malignancies, including pivotal clinical trial data, associated signs and symptoms of serious or life-threatening adverse effects, and the impact of these agents in advanced practice.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Differential Diagnosis and Testing for Hematologic Malignancies
With the backdrop of three unique, real-life case studies, learn how to interpret advancements in diagnostic tests used in risk stratification for hematologic malignancies, including next-generation sequencing for the discovery of novel molecular abnormalities as defined by the World Health Organization and European Leukemia Network.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Advancing the Management of Plasma Cell Dyscrasias
Through expert, case-based discussion, learn how to interpret differential diagnoses of plasma cell dyscrasias, implement the recent changes in the clinical management of the spectrum of multiple myeloma, evaluate the risks and benefits of early treatments for smoldering myeloma, and plan management strategies for patients with solitary plasmacytomas and amyloidosis.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Management of Side Effects for Patients Receiving Multimodality Therapy in Thoracic Oncology
Discover strategies to mitigate adverse events (AEs) of checkpoint inhibitors and radiotherapy for patients with thoracic cancer, and review emerging data regarding managing AEs of EGFR and ALK inhibitors.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
New Drug Updates in Solid Tumors
Review the pharmacology and approved indications of medications for the management of solid tumors, including pivotal clinical trial data, the signs and symptoms of associated serious or life-threatening adverse effects, and each drug’s impact on advanced practice.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Evolving Therapies in the Clinical Management of Melanoma
Take a deep dive into clinical data supporting immunotherapies and emerging targeted therapies for the treatment of advanced/metastatic melanoma, as well as strategies to manage and mitigate associated adverse events.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Preventing and Treating Venous Thrombosis in Oncology
Discover how to interpret recent findings comparing safety and efficacy of “standard” anticoagulants with those of direct oral anticoagulants (DOACs), evaluate the risks and benefits of treatment of DOACs, and monitor and assess patient response to anticoagulant treatment.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
Sequencing Therapies in Renal Cell Carcinoma
Review strategies for how to best utilize immunotherapy in renal cell carcinoma, including tyrosine kinase inhibitors in the adjuvant setting in patients with advanced disease.
Posted: 1/31/2019 / Expires: 1/31/2020
Estimated time to complete: 1 hour
KEYNOTE ADDRESS: Integrating Palliative Care Into the Cancer Care Setting: The Role of the Advanced Practitioner
Review the importance of, and barriers to, integrating palliative care throughout the entire continuum of cancer care, along with supporting data and real-life patient stories, as well as the vital role advanced practitioners play in this evolution of care.
Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)—Optimizing Use of Current Options
Review how to optimize the use of current therapies, including incorporating risk-adapted treatment strategies and keeping up to date with evolving guidelines for evaluating treatment response.
Posted: 7/31/2019 / Expires: 7/31/2020
Estimated time to complete: 30 minutes
Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)—Preparing for Novel Agents
Discover the practice-changing implications of novel mechanisms of action, new combinations, and new administration options.
Posted: 7/31/2019 / Expires: 7/31/2020
Estimated time to complete: 30 minutes
Enhancing Shared Decision Making in Relapsed/Refractory Multiple Myeloma (RRMM)
Learn how to incorporate patient-centered communication and shared decision making in your practice, thereby improving patient and caregiver adherence, satisfaction, and engagement.
Posted: 7/31/2019 / Expires: 7/31/2020
Estimated time to complete: 30 minutes
Case Study 1: HDMTX-Induced AKI in Osteosarcoma
Using the case of a 31-year-old female patient undergoing treatment for osteosarcoma, Nancy Nix, PharmD, BCPS, BCOP, and Kristi Posey, PA, discuss risk factors for acute kidney injury following high-dose methotrexate (HDMTX) treatment, as well as the importance of pretreatment patient counseling and working as a team to quickly identify and treat delayed HDMTX clearance. They also take a deep dive into the consensus guidelines on the use of glucarpidase rescue and how to correlate clinical findings and lab values to increase the timeliness of treatment decision making.
Posted: 9/10/2019 / Expires: 9/10/2020
Estimated time to complete: 30 minutes
Case Study 2: HDMTX-Induced AKI in CNS Lymphoma
Nancy Nix, PharmD, BCPS, BCOP, and Haleigh Mistry, MS, PA-C, discuss the case of a 58-year-old female patient receiving high-dose methotrexate (HDMTX) as part of treatment for central nervous system lymphoma. Together, they review contraindications to HDMTX; the importance of adequate hydration and urine alkalinization prior to initiating therapy; the mechanisms of action of MTX, glucarpidase, and leucovorin; as well as recent studies demonstrating improved outcomes, decreased mortality, and shorter length of hospital stay among patients receiving glucarpidase for HDMTX-induced acute kidney injury.
Posted: 9/10/2019 / Expires: 9/10/2020
Estimated time to complete: 30 minutes
Role of Antibody-Drug Conjugates for Front-Line Therapy in Classical Hodgkin Lymphoma
Amy Goodrich, RN, MSN, CRNP-AC, and Nadia Khan, MD, discuss the role of antibody-drug conjugates in the treatment of classical Hodgkin lymphoma, including mechanism of action, recent approvals, emerging data, and expert guidance on clinical application.
Posted: 2/28/2019 / Expires: 2/28/2020
Estimated time to complete: 30 minutes
Anticipating and Managing Side Effects for Patients With Classical Hodgkin Lymphoma
Amy Goodrich, RN, MSN, CRNP-AC, and Barbara Rogers, CRNP, MN, AOCN®, ANP-BC, review best practices for anticipating and managing side effects for patients being treated for classical Hodgkin lymphoma, including the short- and long-term adverse events associated with chemotherapy, checkpoint inhibitors, and antibody–drug conjugates.
Posted: 2/28/2019 / Expires: 2/28/2020
Estimated time to complete: 30 minutes
Shared Decision-Making: How to Discuss Therapeutic Options With Your Patients Considering Treatment for Classical Hodgkin Lymphoma
Amy Goodrich, RN, MSN, CRNP-AC, and Kevin Nguyen, a patient who was treated for classical Hodgkin lymphoma, discuss his treatment journey from diagnosis through relapse and how shared decision-making between him and his health-care team played an important role in the process.
Posted: 2/28/2019 / Expires: 2/28/2020
Estimated time to complete: 30 minutes
Understanding the Role of Targets and Pathways in the Treatment of Melanoma
Incidence rates of melanoma continue to climb, and while most patients are diagnosed at an early stage, once metastatic, melanoma remains the most deadly of all the cutaneous malignancies. With the discovery of immune checkpoints and therapies that target the MAPK pathway, patients with metastatic melanoma have new treatment options and renewed hope.
Posted: 11/27/2018 / Expires: 11/27/2019
Estimated time to complete: 3 hours
Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events
This supplement to JADPRO has been developed in partnership with the AIM With Immunotherapy Immuno-Oncology Essentials group and Terranova Medica. The Appendix includes 12 Care Step Pathways (CSPs), step-by-step guides that are designed to provide comprehensive assessment and management strategies for toxicities unique to immunotherapies. These CSPs work across tumor types, and each of them is discussed in detail in the supplement articles.
Posted: 3/21/2019 / Expires: 3/21/2020
Estimated time to complete: 3 hours
Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
The article discusses existing and emerging data in HER2+ breast cancer, effectively managing diarrhea and other adverse events associated with treatments, and implementing best practices for the management of HER2+ breast cancer brain metastases.
Posted: 3/21/2019 / Expires: 3/21/2020
Estimated time to complete: 0.5 hour
Narratives on Collaboration: Optimizing Management of Immune-Related Adverse Events
Learn about best practices for managing irAEs from this interactive JADPRO article, which includes videos, polling, downloadable patient tools and resources, and more.
Posted: July 12, 2019 / Expires: July 12, 2020
Estimated time to complete: 1.0 hour